Evidence map›Paper›PMID 37798255›Full record

ArticleCancer science2023

Genotype-phenotype correlation for extracolonic aggressive phenotypes in patients with familial adenomatous polyposis.

Yusaku Shimamoto, Yoji Takeuchi, Shingo Ishiguro, Shin-Ichi Nakatsuka, Hiroshi Yunokizaki, Yasumasa Ezoe, Takeshi Nakajima, Kumiko Tanaka, Ryu Ishihara, Tetsuji Takayama and 4 more

Abstract read
In one paragraph

Article in Cancer science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Adenomatous Polyposis Coli Gene Polyposis-Related Syndromes.The American journal of gastroenterology · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yusaku ShimamotoDepartment of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.ORCID https://orcid.org/0000-0001-7794-3080
Yoji TakeuchiDepartment of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.ORCID https://orcid.org/0000-0003-3814-298X
Shingo IshiguroPCL Osaka Pathology and Cytology Center, Osaka, Japan.
Shin-Ichi NakatsukaDepartment of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka, Japan.
Hiroshi YunokizakiIshikawa Gastroenterology Clinic, Osaka, Japan.
Yasumasa EzoeMedical Ethics and Medical Genetics, School of Public Health, Kyoto University, Kyoto, Japan.
Takeshi NakajimaMedical Ethics and Medical Genetics, School of Public Health, Kyoto University, Kyoto, Japan.
Kumiko TanakaDepartment of Gastroenterology and Oncology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
Ryu IshiharaDepartment of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.
Tetsuji TakayamaDepartment of Gastroenterology and Oncology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.ORCID https://orcid.org/0000-0002-0175-1573
Teruhiko YoshidaDepartment of Genetic Medicine and Services, National Cancer Center Hospital, Tokyo, Japan.
Kokichi SuganoDepartment of Genetic Medicine, Sasaki Foundation, Kyoundo Hospital, Tokyo, Japan.
Michihiro MutohDepartment of Molecular-Targeting Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Hideki IshikawaIshikawa Gastroenterology Clinic, Osaka, Japan.

Funding

Japan Agency for Medical Research and Development 19ck0106271h0003
6 · The paper itself

Abstract

Familial adenomatous polyposis (FAP) patients develop various life-threatening extracolonic comorbidities that appear individually or within a family. This diversity can be explained by the localization of the adenomatous polyposis coli (APC) variant, but few reports provide definitive findings about genotype-phenotype correlations. Therefore, we investigated FAP patients and the association between the severe phenotypes and APC variants. Of 247 FAP patients, 126 patients from 85 families identified to have APC germline variant sites were extracted. These sites were divided into six groups (Regions A to F), and the frequency of severe comorbidities was compared among the patient phenotypes. Of the 126 patients, the proportions of patients with desmoid tumor stage ≥III, number of FGPs ≥1000, multiple gastric neoplasms, gastric neoplasm with high-grade dysplasia, and Spigelman stage ≥III were 3%, 16%, 21%, 12%, and 41%, respectively, while the corresponding rates were 30%, 50%, 70%, 50%, and 80% in patients with Region E (codons 1398-1580) variants. These latter rates were significantly higher than those for patients with variants in other regions. Moreover, the proportion of patients with all three indicators (desmoid tumor stage ≥III, number of FGPs ≥1000, and Spigelman stage ≥III) was 20% for those with variants in Region E and 0% for those with variants in other regions. Variants in Region E indicate aggressive phenotypes, and more intensive management is required.

Indexed as

Adenomatous Polyposis ColiDesmoid TumorsStomach NeoplasmsGenes, APCGenetic Association StudiesGenotypeHumansMutationPhenotypeadenomatous polyposis colidesmoid tumorduodenal neoplasmfamilial adenomatous polyposisgastric lesiongenotype-phenotype correlation

Identifiers

PMID37798255
PMCPMC10728006

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.